Avacta’s Faridoxorubicin Shows Promising Results in Salivary Gland Cancer Trials

Avacta Group plc ( (GB:AVCT) ) has provided an update.

Avacta Group PLC announced promising Phase 1b clinical trial results for its drug faridoxorubicin (AVA6000) in treating salivary gland cancer (SGC), showing a 90% disease control rate across Phase 1a and 1b trials. The trial demonstrated clinically meaningful tumor shrinkage and prolonged progression-free survival, reinforcing the potential of Avacta’s pre|CISION® platform to provide new treatment options for SGC and other solid tumors, with further data expected in the first half of 2026.

The most recent analyst rating on (GB:AVCT) stock is a Hold with a £81.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.

Spark’s Take on GB:AVCT Stock

According to Spark, TipRanks’ AI Analyst, GB:AVCT is a Neutral.

Avacta Group plc’s overall stock score is driven by significant financial challenges and valuation concerns, despite positive technical indicators and promising corporate developments. The company’s reliance on external financing and lack of profitability weigh heavily on its score.

To see Spark’s full report on GB:AVCT stock, click here.

More about Avacta Group plc

Avacta Therapeutics is a clinical-stage biopharmaceutical company focused on expanding the reach of potent cancer therapies through its proprietary pre|CISION® platform. This platform utilizes a tumor-specific protease to deliver highly potent payloads directly to the tumor microenvironment, minimizing exposure to healthy tissues. Avacta’s pipeline includes pre|CISION® peptide drug conjugates and Affimer® drug conjugates, which offer advantages over traditional antibody drug conjugates.

Average Trading Volume: 2,652,138

Technical Sentiment Signal: Hold

Current Market Cap: £334.2M

Find detailed analytics on AVCT stock on TipRanks’ Stock Analysis page.